Xpert BCR-ABL Monitor
Simplified, Rapid Testing for Improved CML Patient Management
The Xpert
® BCR-ABL Monitor assay, which detects the BCR-ABL chromosomal translocation, is a quantitative nested real-time reverse-transcription PCR (RT-PCR) assay, intended as an aid in monitoring the p210 (b2a2 and b3a2) transcript in peripheral blood lymphocytes (PBL) of patients with chronic myelogenous leukemia (CML). This revolutionary assay boasts features not available in current testing methods, including: minimal hands-on time while delivering answers in just over two hours, and unprecedented sensitivity, specificity and reproducibility that are acheived by virtue of the world’s first nested real-time PCR system.
Runs On: GeneXpert® System
Quantitative RT-PCR
Current practice guidelines from Europe Against Cancer and National Comprehensive Cancer Network (NCCN) for management of patients with CML call for use of quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) assays during the initial workup of patients with chronic phase CML, to monitor for minimal residual disease, and to identify patients who may be at a high risk for relapse. RT-PCR has been shown to be an accurate and highly sensitive method for detection of the BCR-ABL fusion gene, and is more sensitive than Fluorescence In Situ Hybridization (FISH) or cytogenetics. Sensitive
An additional advantage of quantitative PCR versus FISH and cytogenetics is the high correlation of PCR results obtained from bone marrow and peripheral blood samples. Therefore, PCR may potentially reduce the bone marrow aspirations currently required in testing patients with CML.
